Category Archives: New R&D models

Decentralized R&D the “winning strategy”? – Apple begs to differ

There is a provocative piece in Aug 20 2012 issue (by Connie Guglielmo) of Forbes on Apple’s R&D, countering Pharma (and Tech) trend of decentralizing such efforts. Besides creating many high-level jobs and even more $B, is this creating a … Continue reading

Posted in General Interest, New R&D models | Leave a comment

 

Share

Innovation Upturn? New Medical Entities /$ Increasing!

A recent posting on Derek Lowe’s “In the Pipeline” presents a dismal view of the returns on R&D in Pharma.   BCG had included a graph (from Bernstein Research) of the trend of new molecular entities (“nme”) per $B spent over … Continue reading

Posted in Financial, Innovation, New R&D models | Tagged , | 4 Comments

 

Share

Another R&D model sea-change?

Reflections on GSK’s new R&D model collaborating with top “academic superstars” Continue reading

Posted in General Interest, New R&D models | 1 Comment

 

Share